{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:37:36Z","timestamp":1760441856594,"version":"3.38.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160508","82160508","82160508","82160508","82160508","82160508","82160508","82160508","82160508"],"award-info":[{"award-number":["82160508","82160508","82160508","82160508","82160508","82160508","82160508","82160508","82160508"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yunnan Applied Basic Research Projects","award":["YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001"],"award-info":[{"award-number":["YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001","YNWRMY-2019-067, 2019FE001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Non-small cell lung cancer (NSCLC) is a common subtype of lung cancer that has received considerable attention for its potential association with rheumatoid arthritis (RA). However, current understanding of the relationship between RA and NSCLC risk remains limited and in-depth studies of molecular mechanisms are lacking.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We obtained transcriptomic data of NSCLC from the Gene Expression Omnibus (GEO) database and performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of differential genes. We then used Mendelian randomisation (MR) analysis to explore the causal relationship between RA and NSCLC, but the results showed no direct causal relationship between RA and NSCLC. In light of this finding, we shifted our research focus to investigate the effect of RA therapeutics on NSCLC risk. A drug-targeted MR analysis of drugs available for the treatment of RA was performed by searching for drugs that target NSCLC differential genes associated with RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found that several of the drugs corresponding to NSCLC differential genes associated with RA are used to treat RA. By drug-targeted MR analysis of drugs, we found that some drugs do have an effect on the risk of developing NSCLC, increasing the risk of developing NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study employed transcriptomic analysis and MR of drug targets to elucidate the potential correlation between RA and the risk of developing NSCLC. The identification of NSCLC differentially expressed genes associated with RA and their drug targets has provided new perspectives for an in-depth understanding of the pathogenesis of NSCLC. Furthermore, an additional immune infiltration analysis demonstrated that, in NSCLC tissues, the infiltration levels of specific immune cell subpopulations, including regulatory T cells (Tregs), activated natural killer cells (NK cells) and unpolarised macrophages (M0), exhibited notable differences. These findings emphasise the significant role that immune cell interactions between RA and NSCLC may play in disease progression. Furthermore, through the analysis of validation histology, we have further confirmed the potential role of differential genes associated with RA in the development of NSCLC. The expression levels of these genes demonstrated significant differences in NSCLC samples, providing a basis for possible future therapeutic targets and biomarkers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41065-025-00396-6","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T05:44:12Z","timestamp":1740635052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the association between rheumatoid arthritis and non-small cell lung cancer risk: a transcriptomic and drug target-based analysis"],"prefix":"10.1186","volume":"162","author":[{"given":"Lyubo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bencheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenjun","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zurui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guojian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lincan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"9","key":"396_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends [J]. Nat Rev Clin Oncol. 2023;20(9):624\u201339.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"396_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jtho.2023.11.011","volume":"19","author":"BL Bermas","year":"2024","unstructured":"Bermas BL, Gerber DE. The joint problem of rheumatoid arthritis and lung Cancer [J]. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2024;19(2):196\u20138.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"396_CR3","doi-asserted-by":"crossref","unstructured":"Cho MH, Cho JH, Eun Y et al. Rheumatoid Arthritis and Risk of Lung Cancer: A Nationwide Cohort Study [J]. Journal of Thoracic Oncology: Official Publication of the International Association For the Study of Lung Cancer. 2024;19(2):216\u2013226.","DOI":"10.1016\/j.jtho.2023.10.006"},{"issue":"3","key":"396_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jtho.2023.12.012","volume":"19","author":"B-G Kim","year":"2024","unstructured":"Kim B-G, Yoon S, Lee SY, et al. How does rheumatoid arthritis increase the risk of lung cancer?? [J]. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2024;19(3):509\u201310.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"2","key":"396_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/ard.43.2.128","volume":"43","author":"P Prior","year":"1984","unstructured":"Prior P, Symmons DP, Hawkins CF, et al. Cancer morbidity in rheumatoid arthritis [J]. Ann Rheum Dis. 1984;43(2):128\u201331.","journal-title":"Ann Rheum Dis"},{"key":"396_CR6","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lin J, You Z, et al. Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: will immunosuppressants work? [J]. Frontiers in Immunology; 2022. p. 13.","DOI":"10.3389\/fimmu.2022.1050876"},{"issue":"3","key":"396_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.semarthrit.2021.03.015","volume":"51","author":"X Wu","year":"2021","unstructured":"Wu X, Peng H, Wen Y, et al. Rheumatoid arthritis and risk of lung cancer: Meta-analysis and Mendelian randomization study [J]. Semin Arthritis Rheum. 2021;51(3):565\u201375.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"396_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","volume":"23","author":"G van Loo","year":"2023","unstructured":"van Loo G, Bertrand MJM. Death by TNF: a road to inflammation [J]. Nat Rev Immunol. 2023;23(5):289\u2013303.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"396_CR9","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1016\/S2665-9913(23)00064-4","volume":"5","author":"KR McCarter","year":"2023","unstructured":"McCarter KR, Wolfgang T, Arabelovic S, et al. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study [J]. Lancet Rheumatol. 2023;5(5):e274\u201383.","journal-title":"Lancet Rheumatol"},{"key":"396_CR10","doi-asserted-by":"crossref","unstructured":"Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis [J]. Volume 17. Arthritis Research & Therapy; 2015. p. 212. 1.","DOI":"10.1186\/s13075-015-0728-9"},{"issue":"5","key":"396_CR11","first-page":"756","volume":"30","author":"P Le Blay","year":"2012","unstructured":"Le Blay P, Mouterde G, Barnetche T, et al. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies [J]. Clin Exp Rheumatol. 2012;30(5):756\u201364.","journal-title":"Clin Exp Rheumatol"},{"issue":"16","key":"396_CR12","doi-asserted-by":"publisher","first-page":"e035008","DOI":"10.1161\/JAHA.124.035008","volume":"13","author":"S Wu","year":"2024","unstructured":"Wu S, Meena D, Yarmolinsky J, et al. Mendelian randomization and bayesian colocalization analysis implicate glycoprotein VI as a potential drug target for cardioembolic stroke in South Asian populations [J]. J Am Heart Association. 2024;13(16):e035008.","journal-title":"J Am Heart Association"},{"issue":"3","key":"396_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ajcnut.2024.01.003","volume":"119","author":"H Dong","year":"2024","unstructured":"Dong H, Xu F, Linghu E. Unraveling the link between plasma caffeine concentrations and inflammatory bowel disease risk through Mendelian randomization [J]. Am J Clin Nutr. 2024;119(3):711\u20135.","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"396_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies [J]. Int J Epidemiol. 2011;40(3):755\u201364.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"396_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s43586-021-00092-5","volume":"2","author":"E Sanderson","year":"2022","unstructured":"Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization [J]. Nat Reviews Methods Primers. 2022;2(1):7.","journal-title":"Nat Reviews Methods Primers"},{"key":"396_CR16","doi-asserted-by":"crossref","unstructured":"Guan M, Jiao Y, Zhou L, Bukhari I. Immune Infiltration Analysis with the CIBERSORT Method in Lung Cancer [J]. Disease Markers. 2022;2022:1\u20137.","DOI":"10.1155\/2022\/3186427"},{"issue":"1","key":"396_CR17","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Mara\u00f1\u00f3n M, et al. Genetic drug target validation using Mendelian randomisation [J]. Nat Commun. 2020;11(1):3255.","journal-title":"Nat Commun"},{"key":"396_CR18","doi-asserted-by":"crossref","unstructured":"Couto-Vieira J, Nicolau-Neto P, Costa EP et al. Multi-cancer V-ATPase molecular signatures: A distinctive balance of subunit C isoforms in esophageal carcinoma [J]. EBioMedicine. 2020;51:102581.","DOI":"10.1016\/j.ebiom.2019.11.042"},{"key":"396_CR19","doi-asserted-by":"crossref","unstructured":"Huang Z, Zhu S, Han Z et al. Proteome-Wide analysis reveals TFEB targets for establishment of a prognostic signature to predict clinical outcomes of colorectal Cancer [J]. Cancers, 2023, 15(3).","DOI":"10.3390\/cancers15030744"},{"key":"396_CR20","doi-asserted-by":"publisher","first-page":"567970","DOI":"10.3389\/fonc.2020.567970","volume":"10","author":"X Li","year":"2020","unstructured":"Li X, Li H, Yang C, et al. Comprehensive analysis of ATP6V1s family members in renal clear cell carcinoma with prognostic values [J]. Front Oncol. 2020;10:567970.","journal-title":"Front Oncol"},{"issue":"1","key":"396_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12964-023-01228-8","volume":"21","author":"Z Lin","year":"2023","unstructured":"Lin Z, Jiang T, Zheng W, et al. N6-methyladenosine (m6A) methyltransferase WTAP-mediated miR-92b-5p accelerates osteoarthritis progression [J]. Cell Communication Signal. 2023;21(1):199.","journal-title":"Cell Communication Signal"},{"issue":"7","key":"396_CR22","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1002\/cam4.3777","volume":"10","author":"Z-L Zeng","year":"2021","unstructured":"Zeng Z-L, Lu J-H, Wang Y, et al. The LncRNA XIST\/miR-125b-2-3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer [J]. Cancer Med. 2021;10(7):2423\u201341.","journal-title":"Cancer Med"},{"key":"396_CR23","doi-asserted-by":"publisher","first-page":"122609","DOI":"10.1016\/j.lfs.2024.122609","volume":"347","author":"ZX Chong","year":"2024","unstructured":"Chong ZX, Ho WY, Yeap SK. Decoding the tumour-modulatory roles of LIMK2 [J]. Life Sci. 2024;347:122609.","journal-title":"Life Sci"},{"issue":"7","key":"396_CR24","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1002\/jcp.30234","volume":"236","author":"H Nafea","year":"2021","unstructured":"Nafea H, Youness RA, Abou-Aisha K, Gad MZ. LncRNA HEIH\/miR-939-5p interplay modulates triple-negative breast cancer progression through NOS2-induced nitric oxide production [J]. J Cell Physiol. 2021;236(7):5362\u201372.","journal-title":"J Cell Physiol"},{"key":"396_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2147\/OTT.S227644","volume":"13","author":"Y Shen","year":"2020","unstructured":"Shen Y, Chen G, Gao H, et al. miR-939-5p contributes to the migration and invasion of pancreatic Cancer by targeting ARHGAP4 [J]. OncoTargets Therapy. 2020;13:389\u201399.","journal-title":"OncoTargets Therapy"},{"issue":"6","key":"396_CR26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3899\/jrheum.091466","volume":"37","author":"JA Singh","year":"2010","unstructured":"Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review [J]. J Rhuematol. 2010;37(6):1096\u2013104.","journal-title":"J Rhuematol"},{"issue":"1","key":"396_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1517\/14740338.2012.633509","volume":"11","author":"TA Kerensky","year":"2012","unstructured":"Kerensky TA, Gottlieb AB, Yaniv S, Au S-c. Etanercept: efficacy and safety for approved indications [J]. Exp Opin Drug Saf. 2012;11(1):121\u201339.","journal-title":"Exp Opin Drug Saf"},{"issue":"5","key":"396_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","volume":"39","author":"DE Furst","year":"2010","unstructured":"Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis [J]. Semin Arthritis Rheum. 2010;39(5):327\u201346.","journal-title":"Semin Arthritis Rheum"},{"key":"396_CR29","doi-asserted-by":"publisher","first-page":"120374","DOI":"10.1016\/j.lfs.2022.120374","volume":"294","author":"B Patel","year":"2022","unstructured":"Patel B, Priefer R. Impact of chronic obstructive pulmonary disease, lung infection, and\/or inhaled corticosteroids use on potential risk of lung cancer [J]. Life Sci. 2022;294:120374.","journal-title":"Life Sci"},{"key":"396_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cyto.2015.09.011","volume":"89","author":"X Qian","year":"2017","unstructured":"Qian X, Chen H, Wu X, et al. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis [J]. Cytokine. 2017;89:34\u201344.","journal-title":"Cytokine"},{"key":"396_CR31","doi-asserted-by":"publisher","first-page":"156265","DOI":"10.1016\/j.cyto.2023.156265","volume":"169","author":"L Liu","year":"2023","unstructured":"Liu L, Liu R, Wei C, et al. The role of IL-17 in lung cancer growth [J]. Cytokine. 2023;169:156265.","journal-title":"Cytokine"},{"issue":"1","key":"396_CR32","doi-asserted-by":"publisher","first-page":"184394","DOI":"10.1016\/j.bbamem.2024.184394","volume":"1867","author":"CH Lo","year":"2025","unstructured":"Lo CH. TNF receptors: Structure-function relationships and therapeutic targeting strategies [J]. Biochim Et Biophys Acta (BBA) - Biomembr. 2025;1867(1):184394.","journal-title":"Biochim Et Biophys Acta (BBA) - Biomembr"},{"issue":"1","key":"396_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41392-023-01530-4","volume":"8","author":"X Zhao","year":"2023","unstructured":"Zhao X, Lu Y, Cui L. Neutrophil-sourced TNF in cancer: Deciphering an intricate orchestrator of immunosuppressive communication in the tumor microenvironment [J]. Signal Transduct Target Therapy. 2023;8(1):272.","journal-title":"Signal Transduct Target Therapy"},{"issue":"6","key":"396_CR34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy [J]. Nat Reviews Clin Oncol. 2019;16(6):356\u201371.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"396_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00262-016-1930-6","volume":"66","author":"I Kwiecien","year":"2017","unstructured":"Kwiecien I, Stelmaszczyk-Emmel A, Polubiec-Kownacka M, et al. Elevated regulatory T cells, surface and intracellular CTLA-4 expression and interleukin-17 in the lung cancer microenvironment in humans [J]. Cancer Immunol Immunother. 2017;66(2):161\u201370.","journal-title":"Cancer Immunol Immunother"},{"key":"396_CR36","doi-asserted-by":"publisher","first-page":"ix431","DOI":"10.1016\/S0923-7534(20)33913-2","volume":"23","author":"EK Vetsika","year":"2012","unstructured":"Vetsika EK, Skalidaki E, Koutoulaki A, et al. Assessment of the predictive\/ prognostic value of the Myeloid-Derived suppressor cells (MDSC) and regulatory T cells (TREGS) in Non-Small cell lung Cancer (NSCLC). Preliminary results [J]. Ann Oncol. 2012;23:ix431.","journal-title":"Ann Oncol"},{"key":"396_CR37","doi-asserted-by":"publisher","first-page":"626193","DOI":"10.3389\/fimmu.2021.626193","volume":"12","author":"Q Jiang","year":"2021","unstructured":"Jiang Q, Yang G, Liu Q, et al. Function and role of regulatory T cells in rheumatoid arthritis [J]. Front Immunol. 2021;12:626193.","journal-title":"Front Immunol"},{"issue":"10","key":"396_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00018-022-04563-0","volume":"79","author":"S Yan","year":"2022","unstructured":"Yan S, Kotschenreuther K, Deng S, Kofler DM. Regulatory T cells in rheumatoid arthritis: functions, development, regulation, and therapeutic potential [J]. Cell Mol Life Sci. 2022;79(10):533.","journal-title":"Cell Mol Life Sci"},{"key":"396_CR39","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fimmu.2016.00152","volume":"7","author":"S Carotta","year":"2016","unstructured":"Carotta S. Targeting NK cells for anticancer immunotherapy: clinical and preclinical approaches [J]. Front Immunol. 2016;7:152.","journal-title":"Front Immunol"},{"issue":"10","key":"396_CR40","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00011-021-01504-8","volume":"70","author":"A Fathollahi","year":"2021","unstructured":"Fathollahi A, Samimi LN, Akhlaghi M, et al. The role of NK cells in rheumatoid arthritis [J]. Inflamm Res. 2021;70(10):1063\u201373.","journal-title":"Inflamm Res"},{"key":"396_CR41","doi-asserted-by":"publisher","first-page":"112198","DOI":"10.1016\/j.intimp.2024.112198","volume":"134","author":"Y Pu","year":"2024","unstructured":"Pu Y, Yang G, Zhou Y, et al. The macrophage migration inhibitory factor is a vital player in Pan-Cancer by functioning as a M0 macrophage biomarker [J]. Int Immunopharmacol. 2024;134:112198.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"396_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology [J]. Nat Reviews Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"2","key":"396_CR43","first-page":"183","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB. Immunopathogenesis Rheumatoid Arthritis [J] Immun. 2017;46(2):183\u201396.","journal-title":"Immunopathogenesis Rheumatoid Arthritis [J] Immun"},{"issue":"12","key":"396_CR44","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","volume":"55","author":"S Alivernini","year":"2022","unstructured":"Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis [J]. Immunity. 2022;55(12):2255\u201370.","journal-title":"Immunity"},{"key":"396_CR45","doi-asserted-by":"crossref","unstructured":"Chatzidionysiou K, di Giuseppe D, Soderling J et al. Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking [J]. RMD Open, 2022, 8(2).","DOI":"10.1136\/rmdopen-2022-002465"},{"issue":"3","key":"396_CR46","doi-asserted-by":"publisher","first-page":"e15069","DOI":"10.1111\/1756-185X.15069","volume":"27","author":"S Fujita","year":"2024","unstructured":"Fujita S, Nakano K, Nagasu A, et al. Prognosis and prognostic factors of lung cancer complications in patients with rheumatoid arthritis [J]. Int J Rheum Dis. 2024;27(3):e15069.","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"396_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F. Tumour necrosis factor and cancer [J]. Nat Rev Cancer. 2009;9(5):361\u201371.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"396_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer [J]. Cell. 2010;140(6):883\u201399.","journal-title":"Cell"},{"issue":"6","key":"396_CR49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J]. Nat Rev Drug Discov. 2011;10(6):417\u201327.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"396_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies [J]. Nat Rev Rheumatol. 2016;12(1):49\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"396_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey [J]. Blood. 2012;119(3):651\u201365.","journal-title":"Blood"},{"key":"396_CR52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1146\/annurev.med.45.1.491","volume":"45","author":"KJ Tracey","year":"1994","unstructured":"Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target [J]. Annu Rev Med. 1994;45:491\u2013503.","journal-title":"Annu Rev Med"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00396-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00396-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00396-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T05:44:24Z","timestamp":1740635064000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00396-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00396-6","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data for this study were derived from public databases, with no additional ethics required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The relevant code is available at .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code involved"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}